Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

• Sponsor: Mayo Clinic (Other)
• Overall Status: Completed
• CT.gov ID: NCT02086552
• Collaborator: National Cancer Institute (NCI) (NIH), Novartis Pharmaceuticals (Industry)
• Enrollment: 28
• Location: 1
• Arm: 1
• Actual Duration (Months): 90.8
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma. Sonidegib and lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may delay multiple myeloma from coming back after a stem cell transplant.

Condition or Disease	Intervention/Treatment	Phase
Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma	Other: Laboratory Biomarker Analysis; Drug: Lenalidomide; Drug: Sonidegib	Phase 2

Detailed Description

PRIMARY OBJECTIVES:

1. To assess the complete response (CR) rate with lenalidomide and sonidegib (LDE225) maintenance following an upfront single autologous stem cell transplant (SCT).

SECONDARY OBJECTIVES:

1. To assess the toxicity of lenalidomide and LDE225 when used as maintenance therapy in patients post autologous SCT.

2. To determine the progression-free survival rate at 1 and 2 years post autologous SCT.

3. To evaluate progression-free survival and overall survival.

TERTIARY OBJECTIVES:

1. To determine the proportion of patients achieving a minimal residual disease (MRD) negative status.

OUTLINE:

Patients receive sonidegib orally (PO) once daily (QD) on days 1-28 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stringent complete response (sCR), CR, very good partial response (VGPR), partial response (PR), minor response (MR), or stable disease (SD) (or unconfirmed [u]sCR, uCR, uVGPR, uPR, uMR) continue treatment in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 90 days for up to 3 years.

Study Design

• Study Type: Interventional
• Actual Enrollment: 28 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma
• Actual Study Start Date: Jan 17, 2014
• Actual Primary Completion Date: Jan 15, 2018
• Actual Study Completion Date: Aug 13, 2021

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Treatment (sonidegib, lenalidomide) Patients receive sonidegib PO QD on days 1-28 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve sCR, CR, VGPR, PR, MR, or SD (or usCR, uCR, uVGPR, uPR, uMR) continue treatment in the absence of disease progression or unacceptable toxicity.

Other: Laboratory Biomarker Analysis; Correlative studies; Drug: Lenalidomide; Given PO; Other Names: CC-5013 CC5013 CDC 501 Revlimid ; Drug: Sonidegib; Given PO; Other Names: ERISMODEGIB LDE-225 LDE225 Odomzo Smoothened Antagonist LDE225

Outcome Measures

Primary Outcome Measures

1. Complete Response, Assessed Using the International Myeloma Working Group (IMWG) Uniform Response Criteria [Up to 2 years]

   A comfirmed Complete Response (CR) is defined as a CR noted as the objective status on 2 consecutive evaluations. To be categorized as a CR, patients must exhibit the following:> Negative immunofixation of serum and urine c, and> Disappearance of any soft tissue plasmacytoma, and> <5% plasma cells in Bone Marrow, and> If the only measurable disease is the serum free light chain (FLC), a normal FLC ratio.> We are reporting the proportion of patients achieving a CR or higher divided by the total number of evaluable patients.> Exact binomial 95% confidence intervals for the true success proportion will be calculated.

Secondary Outcome Measures

1. Overall Survival [Time from SCT to death due to any cause, assessed up to 3 years]

   Overall Survival (OS) is defined as the time from Stem Cell Transplant (SCT) to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.

2. Progression-free Survival (1 Year Survival Rate) [Time from SCT to progression or death due to any cause, assessed at 1 year]

   The progression-free survival time is defined as the time from SCT to progression or death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. Here, we are reporting the proportion of patients that have not had a PFS event one year after SCT.

3. Progression-free Survival [Time from SCT to progression or death due to any cause, assessed at 2 years]

   The progression-free survival time is defined as the time from SCT to progression or death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. Here, we are reporting the proportion of patients that have not had a PFS event two years after SCT.

Other Outcome Measures

1. Proportion of Patients Who Achieve MRD Negative Status [Up to 3 years]

   Exact binomial 95% confidence intervals for the true MRD negative rate will be calculated.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Absolute neutrophil count >= 1500/uL

• Platelet count >= 80,000/uL

• Hemoglobin >= 9.0 g/dL

• Serum total bilirubin =< 1.5 x ULN (upper limit of normal)

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver involvement

• Plasma creatine phosphokinase (CK) < 1.5 x ULN

• Serum creatinine =< 1.5 x ULN or 24-hour clearance >= 50 ml/min

• Diagnosis of symptomatic multiple myeloma (MM)

• Patients should have received single autologous stem cell transplantation 60-120 days prior to enrollment to the trial

• Patients should have received the autologous SCT within 12 months of their diagnosis of myeloma to be eligible for the study

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

• Recovered from toxicity of previous chemotherapy (excludes grade 1 neurotoxicity and hematological toxicity)

• Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care

• Willingness to return to the Mayo Clinic enrolling institution for follow-up

• Measurable disease of multiple myeloma at the time of baseline values for disease assessment as defined by at least one of the following:

• Serum monoclonal protein >= 1.0 g/dL

• = 200 mg of monoclonal protein in the urine on 24 hour electrophoresis

• Serum immunoglobulin free light chain (involved free light chain [FLC]) >=10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio

• NOTE: For patients with no relapse prior to transplant, measurable disease at the time of diagnosis

• NOTE: For patients who have had a disease relapse prior to transplant, measurable disease at the time of the most recent relapse immediately prior to transplant; NOTE: if the patient had treatment for the relapsed disease prior to transplant, the patient must have measurable disease at the time of relapse prior to this therapy

• Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but must be willing to initiate prophylaxis with low molecular weight heparin

• Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to and again within 24 hours of starting lenalidomide and LDE225 and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide and LDE225; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

• Sexually active males must be willing to use a condom (even if they have undergone a prior vasectomy) while having intercourse, while taking lenalidomide and for 4 weeks after stopping treatment

• Patient enrolling to this study must agree to register to the mandatory REVLIMID Risk Evaluation and Mitigation Strategy (REMS [TM]) program, and be willing and able to comply with the requirements of (REVLIMID REMS [TM])

• Patients must be willing to provide biological samples as required by the study

Exclusion Criteria:

• Prior allogeneic bone marrow/peripheral blood stem cell transplant

• Patients with evidence of disease progression post SCT at the time of consideration for the study enrollment will not be included

• Impaired cardiac function or clinically significant heart disease, including any one of the following:

• Angina pectoris within 3 months

• Acute myocardial infarction within 3 months

• Fridericia QT (QTcF) > 450 msec for males and > 470 msec for females on the screening electrocardiogram (ECG)

• A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome

• Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)

• Seroreactivity for human immunodeficiency virus (HIV), human T-lymphotropic virus type I (HTLV I) or II, hepatitis B virus (HBV), hepatitis C virus (HCV)

• Other active malignancy requiring therapy; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix

• Any of the following:

• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (> 5 mIU/mL)

• Patients who are not willing to apply highly effective contraception during the study and through the duration as defined below after the final dose of study treatment

• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must use highly effective contraception during the study and through 6 months after the final dose of study treatment; highly effective contraception is defined as either:

• Total abstinence: when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception

• Sterilization: patient has had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment; in case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment

• Male partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate); (for female study patients, the vasectomized male partner should be the sole partner for that patient)

• Use a combination of the following (both a+b):

• Placement of a non-hormonal intrauterine device (IUD) or non-hormonal intrauterine system (IUS)

• Barrier method of contraception: condom or occlusive cap (diaphragm or cervical vault caps) with spermicidal foam/gel/film/cream/vaginal suppository

• Note: hormonal contraception methods (e.g. oral, injected, implanted) are not allowed

• Note: woman are considered post-menopausal and not child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) levels > 40 mIU/mL and estradiol < 20 pg/mL or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago; in the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential

• Male patient must use highly effective (double barrier) methods of contraception (e.g., spermicidal gel plus condom) for the entire duration of the study, and continuing using contraception and refrain from fathering a child for 6 months following the study drug; a condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the study treatment via seminal fluid

• Sexually active males who are unwilling to use a condom during intercourse while taking drug and for 6 months after stopping investigational medications and agree not to father a child in this period

• Other co-morbidity, which would interfere with patient's ability to participate in the trial, e.g. uncontrolled infection, uncompensated lung disease

• Concurrent chemotherapy, radiotherapy, or any ancillary therapy for treatment of multiple myeloma; NOTE: bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment

• Known allergies to any of the components of the investigational treatment regimen or required ancillary treatments

• Major surgery within 4 weeks prior to registration

• Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study or potentially affect the interpretation of the study data

• Patients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract or known malabsorption syndromes

• Patients who have previously been treated with systemic LDE225 or with other hedgehog pathway inhibitors

• Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as 5-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) inhibitors (statins), clofibrate and gemfibrozil, and that cannot be discontinued at least 2 weeks prior to starting LDE225 treatment; NOTE: if it is essential that the patient stays on a statin to control hyperlipidemia, only pravastatin may be used with extra caution

• Patients who have taken part in an experimental drug study =< 4 weeks prior to registration

• Patients who are receiving treatment with medications known to be moderate and strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)/cytochrome P450, family 3, subfamily A, polypeptide 5 (5) or drugs metabolized by cytochrome P450, family 2, subfamily B, polypeptide 6 (CYP2B6) or cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) that have narrow therapeutic index, and that cannot be discontinued before starting treatment with LDE225

• Patients unwilling or unable to comply with the protocol

• Requirement for anticoagulation with warfarin

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mayo Clinic	Rochester	Minnesota	United States	55905

Sponsors and Collaborators

• Mayo Clinic
• National Cancer Institute (NCI)
• Novartis Pharmaceuticals

Investigators

• Principal Investigator: Francis Buadi, Mayo Clinic

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Aug 9, 2018

More Information

Publications

None provided.

• Responsible Party: Mayo Clinic
• ClinicalTrials.gov Identifier: NCT02086552
• Other Study ID Numbers: MC128B; NCI-2014-00170; MC128B; P30CA015083
• First Posted: Mar 13, 2014
• Last Update Posted: Dec 3, 2021
• Last Verified: Dec 1, 2021

• Additional relevant MeSH terms: Multiple Myeloma; Neoplasms, Plasma Cell; Lenalidomide

Study Results

Participant Flow

Arm/Group Title	Treatment (Sonidegib, Lenalidomide)
Arm/Group Description	Patients receive 400 mg sonidegib PO QD on days 1-28 and 10 mg lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Period Title: Overall Study
STARTED	28
COMPLETED	27
NOT COMPLETED	1

Baseline Characteristics

Arm/Group Title	Treatment (Sonidegib, Lenalidomide)
Arm/Group Description	Patients receive 400 mg sonidegib PO QD on days 1-28 and 10 mg lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Overall Participants	28
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	59.5
Sex: Female, Male (Count of Participants)
Female	13 46.4%
Male	15 53.6%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%
Not Hispanic or Latino	24 85.7%
Unknown or Not Reported	4 14.3%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	1 3.6%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	0 0%
White	27 96.4%
More than one race	0 0%
Unknown or Not Reported	0 0%
Region of Enrollment (participants) [Number]
United States	28 100%

Outcome Measures

1. Primary Outcome

Title	Complete Response, Assessed Using the International Myeloma Working Group (IMWG) Uniform Response Criteria
Description	A comfirmed Complete Response (CR) is defined as a CR noted as the objective status on 2 consecutive evaluations. To be categorized as a CR, patients must exhibit the following:> Negative immunofixation of serum and urine c, and> Disappearance of any soft tissue plasmacytoma, and> <5% plasma cells in Bone Marrow, and> If the only measurable disease is the serum free light chain (FLC), a normal FLC ratio.> We are reporting the proportion of patients achieving a CR or higher divided by the total number of evaluable patients.> Exact binomial 95% confidence intervals for the true success proportion will be calculated.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Of the 28 patients registered, one cancelled prior to treatment and 1 was ineligible due to protocol violation. Therefore 26 patients were used in this analysis.

Arm/Group Title	Treatment (Sonidegib, Lenalidomide)
Arm/Group Description	Patients receive 400 mg sonidegib PO QD on days 1-28 and 10 mg lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Measure Participants	26
Number (95% Confidence Interval) [proportion of patients]	0.48

2. Secondary Outcome

Title	Overall Survival
Description	Overall Survival (OS) is defined as the time from Stem Cell Transplant (SCT) to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.
Time Frame	Time from SCT to death due to any cause, assessed up to 3 years

Outcome Measure Data

Analysis Population Description

All patients that began protocol treatment and were eligible were included in this endpoint.

Arm/Group Title	Treatment (Sonidegib, Lenalidomide)
Arm/Group Description	Patients receive 400 mg sonidegib PO QD on days 1-28 and 10 mg lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Measure Participants	26
Median (95% Confidence Interval) [years]	NA

3. Secondary Outcome

Title	Progression-free Survival (1 Year Survival Rate)
Description	The progression-free survival time is defined as the time from SCT to progression or death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. Here, we are reporting the proportion of patients that have not had a PFS event one year after SCT.
Time Frame	Time from SCT to progression or death due to any cause, assessed at 1 year

Outcome Measure Data

Analysis Population Description

All patients that were treated and evaluable were included in this endpoint.

Arm/Group Title	Treatment (Sonidegib, Lenalidomide)
Arm/Group Description	Patients receive 400 mg sonidegib PO QD on days 1-28 and 10 mg lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Measure Participants	26
Number (95% Confidence Interval) [proportion of participants]	0.88 3.1%

4. Secondary Outcome

Title	Progression-free Survival
Description	The progression-free survival time is defined as the time from SCT to progression or death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. Here, we are reporting the proportion of patients that have not had a PFS event two years after SCT.
Time Frame	Time from SCT to progression or death due to any cause, assessed at 2 years

Outcome Measure Data

Analysis Population Description

All patients that began protocol treatment and were evaluable were included in this endpoint.

Arm/Group Title	Treatment (Sonidegib, Lenalidomide)
Arm/Group Description	Patients receive 400 mg sonidegib PO QD on days 1-28 and 10 mg lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Measure Participants	26
Number (95% Confidence Interval) [proportion of participants]	0.76 2.7%

5. Other Pre-specified Outcome

Title	Proportion of Patients Who Achieve MRD Negative Status
Description	Exact binomial 95% confidence intervals for the true MRD negative rate will be calculated.
Time Frame	Up to 3 years

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

Adverse Events

Time Frame	Adverse events were collected at the end of each 28-day cycle, for up to 18 cycles.
Adverse Event Reporting Description	Adverse events were collected systematically at the end of each 28-day cycle, for up to 18 cycles.
Arm/Group Title	Treatment (Sonidegib, Lenalidomide)
Arm/Group Description	Patients receive 400 mg sonidegib PO QD on days 1-28 and 10 mg lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
All Cause Mortality
	Treatment (Sonidegib, Lenalidomide)
	Affected / at Risk (%)	# Events
Total	0/27 (0%)
Serious Adverse Events
	Treatment (Sonidegib, Lenalidomide)
	Affected / at Risk (%)	# Events
Total	5/27 (18.5%)
Blood and lymphatic system disorders
Febrile neutropenia	1/27 (3.7%)	1
Gastrointestinal disorders
Nausea	1/27 (3.7%)	1
Infections and infestations
Lung infection	1/27 (3.7%)	1
Nervous system disorders
Syncope	1/27 (3.7%)	1
Renal and urinary disorders
Acute kidney injury	1/27 (3.7%)	1
Hematuria	1/27 (3.7%)	1
Vascular disorders
Thromboembolic event	1/27 (3.7%)	1
Other (Not Including Serious) Adverse Events
	Treatment (Sonidegib, Lenalidomide)
	Affected / at Risk (%)	# Events
Total	27/27 (100%)
Blood and lymphatic system disorders
Anemia	3/27 (11.1%)	9
Febrile neutropenia	1/27 (3.7%)	1
Ear and labyrinth disorders
Tinnitus	2/27 (7.4%)	18
Eye disorders
Blurred vision	1/27 (3.7%)	3
Gastrointestinal disorders
Abdominal pain	1/27 (3.7%)	1
Constipation	10/27 (37%)	46
Diarrhea	20/27 (74.1%)	147
Gastritis	1/27 (3.7%)	2
Vomiting	10/27 (37%)	13
General disorders
Fatigue	25/27 (92.6%)	248
Infections and infestations
Bladder infection	1/27 (3.7%)	1
Corneal infection	1/27 (3.7%)	1
Infections and infestations - Other, specify	2/27 (7.4%)	5
Sinusitis	1/27 (3.7%)	1
Investigations
Alanine aminotransferase increased	1/27 (3.7%)	1
Alkaline phosphatase increased	2/27 (7.4%)	2
CPK increased	1/27 (3.7%)	1
Lymphocyte count decreased	5/27 (18.5%)	23
Neutrophil count decreased	23/27 (85.2%)	133
Platelet count decreased	18/27 (66.7%)	85
Weight loss	5/27 (18.5%)	12
White blood cell decreased	19/27 (70.4%)	107
Metabolism and nutrition disorders
Anorexia	3/27 (11.1%)	4
Dehydration	1/27 (3.7%)	1
Musculoskeletal and connective tissue disorders
Arthralgia	2/27 (7.4%)	19
Musculoskeletal and connective tissue disorder - Other, specify	4/27 (14.8%)	16
Myalgia	19/27 (70.4%)	146
Nervous system disorders
Dysgeusia	12/27 (44.4%)	44
Headache	1/27 (3.7%)	3
Peripheral sensory neuropathy	20/27 (74.1%)	187
Respiratory, thoracic and mediastinal disorders
Cough	1/27 (3.7%)	1
Skin and subcutaneous tissue disorders
Alopecia	5/27 (18.5%)	11
Dry skin	1/27 (3.7%)	2
Rash maculo-papular	14/27 (51.9%)	29
Skin and subcutaneous tissue disorders - Other, specify	3/27 (11.1%)	3
Vascular disorders
Hot flashes	2/27 (7.4%)	7
Hypertension	1/27 (3.7%)	1
Thromboembolic event	2/27 (7.4%)	10

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.